Vol. 29, No. 18, Pg. 2
January 26, 2018
On January 26, 2018, BioWorld, The Daily Biopharmaceutical Newscource, published this story:
American Gene Technologies International Inc. (AGT), of Rockville, Md., disclosed completion of the pilot runs of its HIV functional cure automated cell processing protocol. That completes a key milestone of the firm’s planned phase I trial of AGT103-T, a genetically modified autologous T-cell product in development as an HIV functional cure. The company has produced a GMP-grade lentiviral vector stock that will modify HIV-specific T cells to make them immune to HIV entry and depletion, having fully developed the process for treating cells, in an automated unit, which reliably manufactures the cell product, AGT said.